TNF and rheumatoid arthritis: Anti-TNF-α agents have also proved to directly reduce platelet activation in patients with RA, which is a potential mechanism explaining the cardiovascular protective effect of anti-TNF-α therapy (Gasparyan and Kitas, 2016).